Cargando…

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma

PURPOSE: We sought to determine whether the detection of circulating tumor DNA (ctDNA) in samples of patients undergoing chemotherapy for advanced leiomyosarcoma (LMS) is associated with objective response or survival. EXPERIMENTAL DESIGN: Using ultra–low-passage whole-genome sequencing (ULP-WGS) of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madanat-Harjuoja, Laura M., Klega, Kelly, Lu, Yao, Shulman, David S., Thorner, Aaron R., Nag, Anwesha, Tap, William D., Reinke, Denise K., Diller, Lisa, Ballman, Karla V., George, Suzanne, Crompton, Brian D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359745/ https://www.ncbi.nlm.nih.gov/pubmed/35561344 http://dx.doi.org/10.1158/1078-0432.CCR-21-3951

Ejemplares similares

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533
por: Madanat-Harjuoja, Laura M., et al.
Publicado: (2022)

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma
por: Klemen, Nicholas D., et al.
Publicado: (2022)

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
por: Burgener, Justin M., et al.
Publicado: (2021)

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
por: Leung, Eric, et al.
Publicado: (2021)

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
por: Jeannot, Emmanuelle, et al.
Publicado: (2021)

Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients
por: Batool, Syeda Maheen, et al.
Publicado: (2022)

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
por: Lheureux, Stephanie, et al.
Publicado: (2023)

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
por: Lindskrog, Sia V., et al.
Publicado: (2023)

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group
por: Shulman, David S., et al.
Publicado: (2018)

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
por: Henriksen, Tenna Vesterman, et al.
Publicado: (2022)

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group
por: Shulman, David S., et al.
Publicado: (2019)

The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
por: Gopal, Priyanka, et al.
Publicado: (2022)

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
por: Kester, Lennart, et al.
Publicado: (2022)

Learning Individual Survival Models from PanCancer Whole Transcriptome Data
por: Kumar, Neeraj, et al.
Publicado: (2023)

A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)
por: Liyasova, Mariya, et al.
Publicado: (2021)

Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
por: Milewski, David, et al.
Publicado: (2023)

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
por: Suman, Vera J., et al.
Publicado: (2022)

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
por: Larkin, James R., et al.
Publicado: (2022)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
por: Westphalen, C. Benedikt, et al.
Publicado: (2022)

Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
por: Bleach, Rachel, et al.
Publicado: (2021)

Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
por: Zhang, Chaoyang, et al.
Publicado: (2023)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
por: Martin, John D., et al.
Publicado: (2022)

VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
por: Cheng, Vinton W.T., et al.
Publicado: (2022)

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
por: Kessler, Tobias, et al.
Publicado: (2023)

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
por: Tovey, Holly, et al.
Publicado: (2023)

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
por: Hoes, Louisa R., et al.
Publicado: (2022)

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
por: Abbott, Charles W., et al.
Publicado: (2021)

Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma
por: Rockall, Andrea G., et al.
Publicado: (2021)

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
por: Williams, Christopher J.M., et al.
Publicado: (2023)

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
por: Hollis, Robert L., et al.
Publicado: (2022)

Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
por: Fisher, Natalie C., et al.
Publicado: (2022)

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
por: Carmagnani Pestana, Roberto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b5p9ebk7fp2q9i3k9ndld6kj8f